AZD0901 in participants with advanced solid tumours expressing Claudin18.2

Trial Identifier: D9800C00001
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: December 2025
Study Completion Date: December 2026
Condition: Liver Cancer; Gastric Cancer; Esophageal cancer; Pancreatic Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
AU Murdoch, AU, WA6150
AU Randwick, AU, 2031
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H3G 1A4
CA, QC Sherbrooke, QC, CA, J1G 2E8
CN Chengdu, CN, 610041
ES Barcelona, ES, 08035
ES Madrid, ES, 28007
ES Madrid, ES, 28040
GE Tbilisi, GE, 0112
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 227-8577
JP Kitaadachi-gun, JP, 362-0806
JP Koto-ku, JP, 135-8550
JP Nagoya-shi, JP, 464-8681
JP Osakasayama-shi, JP, 589-8511
KR Gyeonggi-do, KR, 13620
KR seoul, KR, 06351
KR Seoul, KR, 05505
KR Seoul, KR, 03080
KR Seoul, KR, 03722
MD Chisinau, MD, MD-2025
MY George Town, MY, 10450
MY Johor Bahru, MY, 81100
MY Kuala Lumpur, MY, 59100
MY Kuching, MY, 93586
MY Selangor, MY, 62250
PL Kraków, PL, 31-501
PL Warszawa, PL, 02-034
SG Bukit Merah, SG, 169610
SG Singapore, SG, 119074
SG Singapore, SG, 308433
SG Singapore, SG, 329563
TW Kaohsiung, TW, 80756
TW Taichung, TW, 404
TW Tainan City, TW, 70403
TW Taipei, TW, 11217
TW Taoyuan, TW, 00333
US, CA Orange, CA, US, 92868
US, CA Palo Alto, CA, US, 94304
US, CA Santa Rosa, CA, US, 95403
US, KY Louisville, KY, US, 40202
US, NY Commack, NY, US, 11725
US, RI Providence, RI, US, 02903
US, TX Houston, TX, US, 77030